Takeda Oncology
Charita Beloncio is an accomplished executive in the oncology sales sector, currently serving as Vice President and Head of US Oncology Sales at Takeda Oncology since June 2019. Prior to this role, Charita held various positions at Pfizer from May 2012 to June 2019, including National Hematology Sales Director, where responsibilities involved leading sales strategies for the Hematology portfolio, with a focus on critical diseases such as Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia. Prior experience also includes serving as Specialty Director of Institutional Sales, overseeing a large team and executing strategic plans across multiple southern states. Charita's educational background includes a Bachelor of Arts in Marketing from Columbia Law School, achieved between August 2008 and May 2011.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.